A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Clinical Trial of Titrating Doses of Nabilone with Gabapentin for the Mitigation of Cannabis Withdrawal Symptoms

Date Added
September 14th, 2022
PRO Number
Pro00122680
Researcher
Aimee McRae-Clark

List of Studies


Keywords
Substance Use
Summary

This research study will include heavy, long-term cannabis users with moderate to severe use desire who want or need to discontinue cannabis use and have previously had symptoms of cannabis withdrawal. Subjects participating in this research study will receive either PP-01 higher dose or lower dose (combination of nabilone and gabapentin in a varied amount), nabilone only, gabapentin only or placebo (inactive substance). This study will assess whether the study drugs help to lessen or alleviate cannabis withdrawal symptoms in study subjects.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu



-- OR --